[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626777":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":16,"locations":7,"responsibleParty":21,"collaborators":7,"id":23,"slug":24,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":28,"acronym":29,"eligibilityCriteria":30,"healthyVolunteers":25,"sex":31,"minAge":32,"maxAge":33,"enrollmentInfo":34,"targetDuration":7,"studyType":37,"phases":7,"briefSummary":38,"conditions":39,"keywords":7,"overallStatus":43,"whyStopped":7,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":7},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Patients with a diagnosis of endometriosis receiving treatment with Relugolix CT, according to clinical practice,","Collection of clinical, demographic, laboratory, instrumental, and treatment data. Data will be collected from the patients' medical records.",[13],{"name":14,"affiliation":5,"role":15},"Cristiano Rossitto","PRINCIPAL_INVESTIGATOR",[17],{"name":14,"role":18,"phone":19,"phoneExt":7,"email":20},"CONTACT","+390630155701","cristiano.rossitto@policlinicogemelli.it",{"type":22,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100626777","relugolix-for-endometriosis-associated-pain-100626777",false,"NCT07440043","Relugolix for Endometriosis Associated Pain","An Ambispective, Single-center Observational Study Evaluating the Effectiveness of Relugolix Combination Therapy in Reducing Endometriosis-associated Pain Over 24 Weeks in a Real-world Clinical Setting","RELAX","Inclusion Criteria:\n\n* Female aged between 18 and 50 years\n* Endometriosis confirmed laparoscopically or radiologically (via ultrasound or MRI)\n* Receiving treatment with Relugolix CT according to clinical practice for at least one month\n* Pain score ≥40 on the VAS scale\n* Regular menstrual cycles, (i.e., not in a menopausal or perimenopausal state)\n* Signed informed consent\n\nExclusion Criteria:\n\n\\- Menopausal status (natural or surgical)","FEMALE","18 Years","50 Years",{"count":35,"type":36},33,"ESTIMATED","OBSERVATIONAL","Endometriosis is a chronic, estrogen-dependent condition frequently associated with pelvic pain and reduced quality of life. Relugolix combination therapy (CT), an oral GnRH receptor antagonist-based treatment, has demonstrated efficacy in randomized clinical trials, but real-world data remain limited.\n\nThe RELAX study is a single-center, ambispective observational study evaluating the effectiveness of relugolix CT in reducing endometriosis-associated pain over 24 weeks in routine clinical practice. The primary endpoint is the change from baseline in pelvic pain measured by the Visual Analog Scale (VAS). Secondary outcomes include changes in pain-related symptoms, ultrasonographic findings, patient satisfaction, and safety.",[40,41,42],"Endometriosis","Endometriosis-related Pain","Pelvic Pain Syndrome","NOT_YET_RECRUITING","2026-02-23",{"date":46,"type":47},"2026-02-27","ACTUAL",{"date":49,"type":36},"2026-02-25",{"date":51,"type":36},"2027-02-28",{"name":5,"class":6}]